During the past decade, Centre Hospitalier Regional De Rimouski conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 8 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 3 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier Regional De Rimouski" #1 sponsor was "Bristol-Myers Squibb" with 5 trials, followed by "Merck Sharp & Dohme LLC" with 3 trials sponsored, "Eidos Therapeutics, a BridgeBio company" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier Regional De Rimouski" #1 collaborator was "NCIC Clinical Trials Group" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 3 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Cancer and Leukemia Group B" with 1 trials as a collaborator and "Central European Cooperative Oncology Group" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier Regional De Rimouski" are "Colorectal Cancer" (3 trials), "Prostatic Neoplasms" (3 trials), "Breast Cancer" (2 trials), "ARDS" (1 trials) and "Amyloid Cardiomyopathy" (1 trials). Many other conditions were trialed in "Centre Hospitalier Regional De Rimouski" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier Regional De Rimouski" are "Drug" (24 trials), "Biological" (9 trials), "Genetic" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (5 trials), "Placebo" (4 trials), "Docetaxel" (3 trials), "Pembrolizumab" (3 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier Regional De Rimouski" are 22 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Hospitalier Regional De Rimouski". undefined are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 12 completed trials in Centre Hospitalier Regional De Rimouski, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier Regional De Rimouski, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".